For how we live.
A Global Burden of Disease analysis puts substance use disorder prevalence at 0.78% across the Arab League in 2023, about 63% below the global figure — yet women's opioid prevalence topped men's in 19 of 22 countries.
There is no approved drug for methamphetamine use disorder. In 339 patients treated in ordinary clinics, a generic antidepressant cut use by about two days a month more than placebo, with more dropouts from side-effects.
In 273,466 people with substance-related hospital admissions, psychosis was far more common after hallucinogen admissions, until adjustment for preexisting conditions erased the link.
Compared with a diabetes drug from another class, GLP-1 agonists were followed by fewer new diagnoses of alcohol, opioid, nicotine and other substance use disorders.
A national registry analysis found the highest burden among 20-to-29-year-olds and a notable rise among girls aged 10 to 19, with rates concentrated in the Sierra region.